DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2008/0274913 A1 Lee (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2008/0274913 A1 Lee (43) Pub US 200802749 13A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0274913 A1 Lee (43) Pub. Date: Nov. 6, 2008 (54) MULTIPLEX ARRAYUSEFUL FOR (86). PCT No.: PCT/US2O06/020810 ASSAYING PROTEIN-PROTEIN INTERACTION S371 (c)(1), (2), (4) Date: Jun. 20, 2008 (75) Inventor: Kevin Lee, New York, NY (US) (30) Foreign Application Priority Data Correspondence Address: May 27, 2005 (US) .................................... 60685565 INVITROGEN CORPORATION O O CFO INTELLEVATE Publication Classification P.O. BOX S2OSO (51) Int. Cl. MINNEAPOLIS, MN 55402 (US) C40B 40/02 (2006.01) (52) U.S. Cl. .......................................................... 506/14 (73) Assignee: ision Corporation, Carlsbad (57) ABSTRACT The described invention shows how multiple interactions (21) Appl. No.: 11/915,689 between two proteins of interest can be determined by observ ing activation or lack thereof of intracellular proteins, follow (22) PCT Filed: May 30, 2006 ing interaction of ligand and receptor. 7TM Receptor 2222 Nuclear Localization Transcription Reporter Gene induction Factor tTA Protease Cleavage Site Arrestin TEV Protease Patent Application Publication Nov. 6, 2008 Sheet 1 of 13 US 2008/02749 13 A1 Ø uo?onpu]eues)d??Jode>+ Patent Application Publication Nov. 6, 2008 Sheet 2 of 13 US 2008/02749 13 A1 Epinephrine and isoproterenol Dose Responses 110 100 90 80 70 60 -o- Epinephrine EC50 E 227 nM 50 a soproterenol i 40 EC50 = 51.1 nM 30 20 10 Drug FIG. 2A Alprenolol Dose inhibition Curve (1 uM Epinephrine) 03-06-03 i Log Alprenolol FIG. 2B Patent Application Publication Nov. 6, 2008 Sheet 3 of 13 US 2008/02749 13 A1 Vasopressin Dose Response Curve 110 100 -o- Vasopressin 50 EC50 E 3.3 nM i No Ligand 10 uMDopamine D2 / B-arr 2 D21B-arr 2 D21 B-arr 1 D21B-arr 1 (A383) (A383) FIG. 4 Patent Application Publication Nov. 6, 2008 Sheet 4 of 13 US 2008/02749 13 A1 BetaAR-> lacz (Clone 41) 8OOO.O BetaAR -> lacz 7OOO.O 6OOOO 5000.0 4000.0 3OOOO 2000.0 - - 1 OOOO No Ligand +lso +Dopa +lso-Dop F.G. 5A D2 -> luc (Clone 1H10) 6OOOO.O 5OOOOO 40000.0 3OOOOO 2 O O O O. 10OOO.O 0.0 No Ligand +lso +Dopa +lso--Dop F.G. 5B Patent Application Publication Nov. 6, 2008 Sheet 5 of 13 US 2008/02749 13 A1 OPRK-AVPR2 LaCZ Multiplex Data ADRB2-AVPR2 120.00 1OOOO 80.00 60.00 40.00 20.00 O.OO No Ligand U69,593 lso 10 SO + 10 uM uM U69,593 F.G. 6 Patent Application Publication Nov. 6, 2008 Sheet 6 of 13 US 2008/02749 13 A1 EGFR(L) I SH2 Tev Patent Application Publication Nov. 6, 2008 Sheet 7 of 13 US 2008/02749 13 A1 Effect of IFNalpha and IFNbeta on IFN Type I Receptors in HTL5B8.1 No Ligand 300 250 200 150 100 50 Treatments FIG. 8 Patent Application Publication Nov. 6, 2008 Sheet 8 of 13 US 2008/02749 13 A1 Dose Response Curve for IFNalpha in HTL5B8.1 350 3OO 250 200 1. g 150 C 1OO EC50: 7621 u/ml 50 O O 1 2 3 4. 5 6 Log10 IFNalpha FIG. 9 Effect of IFNalpha on IFN Type I Receptors in CHO-K Cells -FN + 5000 u/ml IFNalpha d - na g 4. pFRLuc-R1(L)-GAL4-NF-KB +R2.2-TeV--STAT1+STAT2 pFRLuc-pCDNA3 Treatments FIG. 10 Patent Application Publication Nov. 6, 2008 Sheet 9 of 13 US 2008/02749 13 A1 ADRB1 (9029) pro293a, Alprenolol I Yohimbine 05.18.05 400 -o- Alprenolol IC50 = 1.50 nM 100 -- Yohimbine IC50 = n.a. - 12 - 11 - 10 -9 -8 -7 -6 -5 -4 logantagonist, M FIG 11A ADRB2 (374) pro293a, Alprenolol I Yohimbine 05.18.05 -o- Aprenolol IC50 = 115 pM -- Yohimbine IC50 F n.a. -12 -11 -lo -9 8 7 6 5 4 logantagonist, M) FIG. 11B Patent Application Publication Nov. 6, 2008 Sheet 10 of 13 US 2008/02749 13 A1 ADRA2A (9027) Pro293a, Alprenolol I Yohimbine 05.18.05 -o- Alprenolol IC50 = n.a. -- Yohimbine IC50 = 1.69 nM 300 100 - 12 -11 - 10 -9 -8 -7 -6 -5 -4 Logantagonist, M FIG. 11C ADRA2B (9019) pro293a, Alprenolol I Yohimbine 05.18.05 225 -o- Alprenolol IC50 = n.a. 2OO -- Yohimbine IC50 = 4.62 mm 175 150 125 i 100 75 50 25 -12 -11 -10 -9 -8 -7 -6 -5 -4 logantagonist, MI FIG. 11D Patent Application Publication Nov. 6, 2008 Sheet 11 of 13 US 2008/02749 13 A1 ADRA2C (9025) Pro293a, Alprenolol I Yohimbine 05.18.05 -- Alprenolol IC50 = n.a. -- Yohimbine IC50 = 11.5 nM -12 - 11 - 10 -9 -8 -7 -6 -5 -4 Logantagonist, M F.G. 11E ADRB1 (9029) UK 14,304 || US 13 Isoproterenol 05.06.05 EC50 = n.a. 350 -v- isoproterenol EC50 = 30.5 nM 300 -12 -11 -10 -9 -8 7 6 5 4 LogLigand, M F.G. 11 F Patent Application Publication Nov. 6, 2008 Sheet 12 of 13 US 2008/02749 13 A1 ADRB2 (374) UK 14,304. 1 isoproterenol 05.06.05 350 31. 200 • US50 13 F .a. 150 -- isoproterenol EC50 = 37.3 nM 1 OO 50 O -12 -11 - 10 -9 -8 -7 -6 -5 -4 LogLigand, MI F.G. 11G ADRB2A (9027) UK 14,304 f isoproterenol 05.06.05 7O -- UK 14,304 EC50 = 4.12 nM 60 -- isoproterenol EC50 = 28.8 uM 50 up 40 D - a 30 2O 10 - O -12 -11 -10 -9 -8 -7 -6 -5 4 LogLigand, M F.G. 11H Patent Application Publication Nov. 6, 2008 Sheet 13 of 13 US 2008/02749 13 A1 ADRA2B (9019) UK 14,3041 isoproterenol 05.06.05 -o- UK 14,304 EC50 = 188 nM -- isoproterenol EC50 = 13.0 uM () O - 1. -12 -11 - 10 -9 -8 -7 -6 -5 -4 LogLigand, M FIG. 11 ADRA2C (9025) UK 14,304 Isoproterenol 05.06.05 70 -- UK 14,304 EC50 = 94.4 nM -- isoproterenol 60 EC50 = 9.0 uM 50 n 40 O - 2 30 2O 1O O -12 -11 - 10 -9 -8 -7 -6 -5 -4 LogLigand, M FIG 11 US 2008/02749 13 A1 Nov. 6, 2008 MULTIPLEX ARRAYUSEFUL FOR ligand and receptor stimulates guanine nucleotide exchange ASSAYING PROTEIN-PROTEIN and dissociation of the G protein heterotrimer into C. and By INTERACTION Subunits. 0005. Both the GTP-bound C. subunit and the By dimer can FIELD OF THE INVENTION act to regulate various cellular effector proteins, including 0001. This invention relates to methods for determining adenylyl cyclase and phospholipase C (PLC). In conventional interaction between molecules of interest. More particularly, cell based assays for GPCRs, receptor activity is monitored it relates to determining if a particular Substance referred to as by measuring the output of a G-protein regulated effector the test compound modulates the interaction of two or more pathway, such as the accumulation of cAMP that is produced specific proteins of interest, via determining activation of a by adenylyl cyclase, or the release of intracellular calcium, reporter gene in a cell, where the activation, or lack thereof, which is stimulated by PLC activity. results from the modulation or its absence. The determination 0006 Conventional G-protein based, signal transduction occurs using transformed or transfected cells, which are also assays have been difficult to develop for Some targets, as a a feature of the invention, as are the agents used to transform result of two major issues. or transfect them. More particularly, the inventions relates to 0007 First, different GPCRs are coupled to different G what will be referred to as “multiple arrays, which permit an protein regulated signal transduction pathways, and G-pro investigator to screen test compounds against a plurality of tein based assays are dependent on knowing the G-protein proteins, such as receptors, GPCRs in particular. specificity of the target receptor, or require engineering of the cellular system, to force coupling of the target receptor to a BACKGROUND AND RELATED ART particular effect or pathway. Second, all cells express a large 0002 The study of protein/protein interaction, as exem number of endogenous GPCRs, as well as other signaling plified, e.g., by the identification of ligands for receptors, is an factors. As a result, the effector pathways that are measured area of great interest. Even when a ligand or ligands for a may be modulated by other endogenous molecules in addi given receptor are known, there is interest in identifying more tion to the target GPCR, potentially leading to false results. effective or more selective ligands. GPCRs will be discussed 0008 Regulation of G-protein activity is not the only hereinas a non-exclusive example of a class of proteins which result of ligand/GPCR binding. Luttrell, et al., J. Cell Sci., can be studied in this way. 115:455-465 (2002), and Ferguson, Pharmacol. Rev., 53:1- 0003. The G-protein coupled receptors, or “GPCRs' here 24 (2001), both of which are incorporated by reference, after, are the largest class of cell Surface receptors known for review other activities which lead to termination of the GPCR humans. Among the ligands recognized by GPCRs are hor signal. These termination processes prevent excessive cell mones, neurotransmitters, peptides, glycoproteins, lipids, stimulation, and enforce temporal linkage between extracel nucleotides, and ions. They also act as receptors for light, lular signal and corresponding intracellular pathway. odors, pheromones, and taste. Given these various roles, it is 0009. In the case of binding of an agonist to GPCR, serine perhaps not surprising that they are the Subject of intense and threonine residues at the C terminus of the GPCR mol research, seeking to identify drugs useful in various condi ecule are phosphorylated.
Load more

Recommended publications
  • Strategies to Increase ß-Cell Mass Expansion
    This electronic thesis or dissertation has been downloaded from the King’s Research Portal at https://kclpure.kcl.ac.uk/portal/ Strategies to increase -cell mass expansion Drynda, Robert Lech Awarding institution: King's College London The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without proper acknowledgement. END USER LICENCE AGREEMENT Unless another licence is stated on the immediately following page this work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ You are free to copy, distribute and transmit the work Under the following conditions: Attribution: You must attribute the work in the manner specified by the author (but not in any way that suggests that they endorse you or your use of the work). Non Commercial: You may not use this work for commercial purposes. No Derivative Works - You may not alter, transform, or build upon this work. Any of these conditions can be waived if you receive permission from the author. Your fair dealings and other rights are in no way affected by the above. Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 Strategies to increase β-cell mass expansion A thesis submitted by Robert Drynda For the degree of Doctor of Philosophy from King’s College London Diabetes Research Group Division of Diabetes & Nutritional Sciences Faculty of Life Sciences & Medicine King’s College London 2017 Table of contents Table of contents .................................................................................................
    [Show full text]
  • Orbital Scintigraphy with the Somatostatin Receptor Tracer 99Mtc-P829 in Patients with Graves’ Disease
    CLINICAL INVESTIGATIONS Orbital Scintigraphy with the Somatostatin Receptor Tracer 99mTc-P829 in Patients with Graves’ Disease Georg Burggasser, MD1; Ingrid Hurtl, MD2; Wolfgang Hauff, MD1; Julius Lukas, MD1; Michaela Greifeneder, MD2; Bamdad Heydari, MD2; Arnulf Thaler, MD1; Andreas Wedrich, MD1; and Irene Virgolini, MD2,3 1Department of Ophthalmology and Optometry, University of Vienna, Vienna, Austria; 2Institute of Nuclear Medicine, Vienna City Hospital Lainz, Vienna, Austria; and 3Ludwig Boltzmann Institute of Experimental Oncology and Photodynamic Therapy, Vienna City Hospital Lainz, Vienna, Austria documented regarding the NOSPECS classification as well as 99m Receptors for somatostatin (SST) (SSTR) are expressed on var- the SNI. Conclusion: In TAO, Tc-P829 yields high orbital ious tumor cells as well as on activated lymphocytes. Previous binding with good clinical correlation. The better image quality data have shown that 99mTc-P829 binds with high affinity to due to the high energy of technetium, the lower radiation dose many different types of tumor cells as well as to leukocytes via for patients and personnel, and the short acquisition protocol 99m 111 the human hSSTR2, hSSTR3, and hSSTR5 target receptors. favor SSTR scintigraphy with Tc-P829 over In-labeled Consequently, 99mTc-P829 was successfully introduced as a compounds. The in-house availability of the radiotracer and peptide tracer for tumor imaging. In this study, we evaluated the cost-effectiveness are further advantages. orbital uptake of 99mTc-P829 in patients with active and inactive Key Words: somatostatin receptor; somatostatin receptor im- thyroid-associated orbitopathy (TAO), accompanied by lympho- aging; 99mTc-P829; 99mTc-NeoSpect; 99mTc-NeoTect; Graves’ cyte infiltration in the acute stage and by muscle fibrosis in the disease; thyroid associated orbitopathy chronic stage of the disease.
    [Show full text]
  • The Histamine H4 Receptor: a Novel Target for Safe Anti-Inflammatory
    GASTRO ISSN 2377-8369 Open Journal http://dx.doi.org/10.17140/GOJ-1-103 Review The Histamine H4 Receptor: A Novel Target *Corresponding author Maristella Adami, PhD for Safe Anti-inflammatory Drugs? Department of Neuroscience University of Parma Via Volturno 39 43125 Parma Italy * 1 Tel. +39 0521 903943 Maristella Adami and Gabriella Coruzzi Fax: +39 0521 903852 E-mail: [email protected] Department of Neuroscience, University of Parma, Via Volturno 39, 43125 Parma, Italy Volume 1 : Issue 1 1retired Article Ref. #: 1000GOJ1103 Article History Received: May 30th, 2014 ABSTRACT Accepted: June 12th, 2014 th Published: July 16 , 2014 The functional role of histamine H4 receptors (H4Rs) in the Gastrointestinal (GI) tract is reviewed, with particular reference to their involvement in the regulation of gastric mucosal defense and inflammation. 4H Rs have been detected in different cell types of the gut, including Citation immune cells, paracrine cells, endocrine cells and neurons, from different animal species and Adami M, Coruzzi G. The Histamine H4 Receptor: a novel target for safe anti- humans; moreover, H4R expression was reported to be altered in some pathological conditions, inflammatory drugs?. Gastro Open J. such as colitis and cancer. Functional studies have demonstrated protective effects of H4R an- 2014; 1(1): 7-12. doi: 10.17140/GOJ- tagonists in several experimental models of gastric mucosal damage and intestinal inflamma- 1-103 tion, suggesting a potential therapeutic role of drugs targeting this new receptor subtype in GI disorders, such as allergic enteropathy, Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS) and cancer. KEYWORDS: Histamine H4 receptor; Stomach; Intestine.
    [Show full text]
  • Transcriptomic Profiling of Pancreatic Alpha, Beta and Delta Cell Populations Identifies Delta Cells As a Principal Target for Ghrelin in Mouse Islets
    Diabetologia (2016) 59:2156–2165 DOI 10.1007/s00125-016-4033-1 ARTICLE Transcriptomic profiling of pancreatic alpha, beta and delta cell populations identifies delta cells as a principal target for ghrelin in mouse islets Alice E. Adriaenssens1 & Berit Svendsen2,3 & Brian Y. H. Lam1 & Giles S. H. Yeo1 & Jens J. Holst2,3 & Frank Reimann1 & Fiona M. Gribble 1 Received: 15 March 2016 /Accepted: 1 June 2016 /Published online: 7 July 2016 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract using islets with delta cell restricted expression of the calcium Aims/hypothesis Intra-islet and gut–islet crosstalk are critical reporter GCaMP3, and in perfused mouse pancreases. in orchestrating basal and postprandial metabolism. The aim Results A database was constructed of all genes expressed in of this study was to identify regulatory proteins and receptors alpha, beta and delta cells. The gene encoding the ghrelin underlying somatostatin secretion though the use of receptor, Ghsr, was highlighted as being highly expressed transcriptomic comparison of purified murine alpha, beta and enriched in delta cells. Activation of the ghrelin receptor and delta cells. raised cytosolic calcium levels in primary pancreatic delta Methods Sst-Cre mice crossed with fluorescent reporters were cells and enhanced somatostatin secretion in perfused used to identify delta cells, while Glu-Venus (with Venus re- pancreases, correlating with a decrease in insulin and gluca- ported under the control of the Glu [also known as Gcg]pro- gon release. The inhibition of insulin secretion by ghrelin was moter) mice were used to identify alpha and beta cells.
    [Show full text]
  • Functional and Molecular Heterogeneity Of
    ARTICLE https://doi.org/10.1038/s41467-020-15716-9 OPEN Functional and molecular heterogeneity of D2R neurons along dorsal ventral axis in the striatum ✉ Emma Puighermanal1,2 , Laia Castell1, Anna Esteve-Codina 3, Su Melser4,5, Konstantin Kaganovsky 6, Charleine Zussy1, Jihane Boubaker-Vitre1, Marta Gut3,7, Stephanie Rialle1, Christoph Kellendonk8,9, Elisenda Sanz2, Albert Quintana 2, Giovanni Marsicano4,5, Miquel Martin1, Marcelo Rubinstein10,11,12, ✉ Jean-Antoine Girault 13,14,15, Jun B. Ding6 & Emmanuel Valjent 1 1234567890():,; Action control is a key brain function determining the survival of animals in their environ- ment. In mammals, neurons expressing dopamine D2 receptors (D2R) in the dorsal striatum (DS) and the nucleus accumbens (Acb) jointly but differentially contribute to the fine reg- ulation of movement. However, their region-specific molecular features are presently unknown. By combining RNAseq of striatal D2R neurons and histological analyses, we identified hundreds of novel region-specific molecular markers, which may serve as tools to target selective subpopulations. As a proof of concept, we characterized the molecular identity of a subcircuit defined by WFS1 neurons and evaluated multiple behavioral tasks after its temporally-controlled deletion of D2R. Consequently, conditional D2R knockout mice displayed a significant reduction in digging behavior and an exacerbated hyperlocomotor response to amphetamine. Thus, targeted molecular analyses reveal an unforeseen hetero- geneity in D2R-expressing striatal neuronal populations, underlying specific D2R’s functional features in the control of specific motor behaviors. 1 IGF, CNRS, INSERM, Université Montpellier, Montpellier, France. 2 Neuroscience Institute, Department of Cell Biology, Physiology and Immunology, Autonomous University of Barcelona, Bellaterra, Spain.
    [Show full text]
  • Novel Drug-Like Somatostatin Receptor 4 Agonists Are Potential Analgesics for Neuropathic Pain
    International Journal of Molecular Sciences Article Novel Drug-Like Somatostatin Receptor 4 Agonists are Potential Analgesics for Neuropathic Pain 1,2, 3, 1,2 4 1,2 Boglárka Kántás y, Rita Börzsei y, Éva Sz˝oke ,Péter Bánhegyi , Ádám Horváth , 1,2 1,2 1 1,2, Ágnes Hunyady , Éva Borbély , Csaba Hetényi , Erika Pintér y and 1,2, , Zsuzsanna Helyes * y 1 Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Szigeti str. 12, H-7624 Pécs, Hungary 2 Szentágothai Research Centre and Centre for Neuroscience, University of Pécs, Ifjúság str. 20, H-7624 Pécs, Hungary 3 Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Szigeti str. 12, H-7624 Pécs, Hungary 4 Avicor Ltd., Herman Ottó str. 15, H-1022 Budapest, Hungary * Correspondence: [email protected] These authors contributed equally to this work. y Received: 14 October 2019; Accepted: 9 December 2019; Published: 11 December 2019 Abstract: Somatostatin released from the capsaicin-sensitive sensory nerves mediates analgesic and anti-inflammatory effects via the somatostatin sst4 receptor without endocrine actions. Therefore, sst4 is considered to be a novel target for drug development in pain including chronic neuropathy, which is an emerging unmet medical need. Here, we examined the in silico binding, the sst4-linked G-protein activation on stable receptor expressing cells (1 nM to 10 µM), and the effects of our novel pyrrolo-pyrimidine molecules in mouse inflammatory and neuropathic pain models. All four of the tested compounds (C1–C4) bind to the same binding site of the sst4 receptor with similar interaction energy to high-affinity reference sst4 agonists, and they all induce G-protein activation.
    [Show full text]
  • Table 2. Significant
    Table 2. Significant (Q < 0.05 and |d | > 0.5) transcripts from the meta-analysis Gene Chr Mb Gene Name Affy ProbeSet cDNA_IDs d HAP/LAP d HAP/LAP d d IS Average d Ztest P values Q-value Symbol ID (study #5) 1 2 STS B2m 2 122 beta-2 microglobulin 1452428_a_at AI848245 1.75334941 4 3.2 4 3.2316485 1.07398E-09 5.69E-08 Man2b1 8 84.4 mannosidase 2, alpha B1 1416340_a_at H4049B01 3.75722111 3.87309653 2.1 1.6 2.84852656 5.32443E-07 1.58E-05 1110032A03Rik 9 50.9 RIKEN cDNA 1110032A03 gene 1417211_a_at H4035E05 4 1.66015788 4 1.7 2.82772795 2.94266E-05 0.000527 NA 9 48.5 --- 1456111_at 3.43701477 1.85785922 4 2 2.8237185 9.97969E-08 3.48E-06 Scn4b 9 45.3 Sodium channel, type IV, beta 1434008_at AI844796 3.79536664 1.63774235 3.3 2.3 2.75319499 1.48057E-08 6.21E-07 polypeptide Gadd45gip1 8 84.1 RIKEN cDNA 2310040G17 gene 1417619_at 4 3.38875643 1.4 2 2.69163229 8.84279E-06 0.0001904 BC056474 15 12.1 Mus musculus cDNA clone 1424117_at H3030A06 3.95752801 2.42838452 1.9 2.2 2.62132809 1.3344E-08 5.66E-07 MGC:67360 IMAGE:6823629, complete cds NA 4 153 guanine nucleotide binding protein, 1454696_at -3.46081884 -4 -1.3 -1.6 -2.6026947 8.58458E-05 0.0012617 beta 1 Gnb1 4 153 guanine nucleotide binding protein, 1417432_a_at H3094D02 -3.13334396 -4 -1.6 -1.7 -2.5946297 1.04542E-05 0.0002202 beta 1 Gadd45gip1 8 84.1 RAD23a homolog (S.
    [Show full text]
  • Edinburgh Research Explorer
    Edinburgh Research Explorer International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list Citation for published version: Davenport, AP, Alexander, SPH, Sharman, JL, Pawson, AJ, Benson, HE, Monaghan, AE, Liew, WC, Mpamhanga, CP, Bonner, TI, Neubig, RR, Pin, JP, Spedding, M & Harmar, AJ 2013, 'International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands', Pharmacological reviews, vol. 65, no. 3, pp. 967-86. https://doi.org/10.1124/pr.112.007179 Digital Object Identifier (DOI): 10.1124/pr.112.007179 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Pharmacological reviews Publisher Rights Statement: U.S. Government work not protected by U.S. copyright General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 1521-0081/65/3/967–986$25.00 http://dx.doi.org/10.1124/pr.112.007179 PHARMACOLOGICAL REVIEWS Pharmacol Rev 65:967–986, July 2013 U.S.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Histamine Receptors
    Tocris Scientific Review Series Tocri-lu-2945 Histamine Receptors Iwan de Esch and Rob Leurs Introduction Leiden/Amsterdam Center for Drug Research (LACDR), Division Histamine is one of the aminergic neurotransmitters and plays of Medicinal Chemistry, Faculty of Sciences, Vrije Universiteit an important role in the regulation of several (patho)physiological Amsterdam, De Boelelaan 1083, 1081 HV, Amsterdam, The processes. In the mammalian brain histamine is synthesised in Netherlands restricted populations of neurons that are located in the tuberomammillary nucleus of the posterior hypothalamus.1 Dr. Iwan de Esch is an assistant professor and Prof. Rob Leurs is These neurons project diffusely to most cerebral areas and have full professor and head of the Division of Medicinal Chemistry of been implicated in several brain functions (e.g. sleep/ the Leiden/Amsterdam Center of Drug Research (LACDR), VU wakefulness, hormonal secretion, cardiovascular control, University Amsterdam, The Netherlands. Since the seventies, thermoregulation, food intake, and memory formation).2 In histamine receptor research has been one of the traditional peripheral tissues, histamine is stored in mast cells, eosinophils, themes of the division. Molecular understanding of ligand- basophils, enterochromaffin cells and probably also in some receptor interaction is obtained by combining pharmacology specific neurons. Mast cell histamine plays an important role in (signal transduction, proliferation), molecular biology, receptor the pathogenesis of various allergic conditions. After mast cell modelling and the synthesis and identification of new ligands. degranulation, release of histamine leads to various well-known symptoms of allergic conditions in the skin and the airway system. In 1937, Bovet and Staub discovered compounds that antagonise the effect of histamine on these allergic reactions.3 Ever since, there has been intense research devoted towards finding novel ligands with (anti-) histaminergic activity.
    [Show full text]
  • See Also Figure 1
    Figure S1. Box-and-whisker plots depicting the range of expression values per developmental stage, with DESeq normalization (A) or quantile normalization (B). See also Figure 1. Figure S2. Lv-Setmar expression has low variation over developmental time. A. A plot of Lv-setmar versus Lv-ubiquitin expression over time demonstrates that Lv-setmar exhibits less temporal variation than Lv-ubiquitin. B. A representative gel showing Lv-setmar qPCR products amplified from cDNAs representing each sequenced stage in this study, demonstrating comparable product levels and an absence of spurious amplification products. See also Figure 1E. Figure S3. LvEDGE database. Screen shots showing the home page (A), the search window (B), an example search with a temporal expression plot (C), and the numerical data reflected in the plot (D) for the LvEDGE public database, which hosts the data described herein. stage 1 2 3 4 5 6 7 8 9 10 11 Category Subcategory 2-cell 60-cell EB HB TVP MB EG MG LG EP LP meiotic Cell Division Cytokinesis Mitosis checkpoint cell division recombination cell cycle stem cell left-right cell left-right Development maintenance asymmetry morphogenesis asymmetry regulation of multicellular organismal process cell soma cell soma Gene Expression chromatin SWI/SNF Control Chromatin modification chromatin binding complex methylated histone Binding negative sequence- sequence- sequence- regulation of sequence- specific DNA specific DNA specific DNA transcription specific DNA sequence-specific DNA binding binding binding binding factor activity
    [Show full text]
  • Technical Note, Appendix: an Analysis of Blood Processing Methods to Prepare Samples for Genechip® Expression Profiling (Pdf, 1
    Appendix 1: Signature genes for different blood cell types. Blood Cell Type Source Probe Set Description Symbol Blood Cell Type Source Probe Set Description Symbol Fraction ID Fraction ID Mono- Lympho- GSK 203547_at CD4 antigen (p55) CD4 Whitney et al. 209813_x_at T cell receptor TRG nuclear cytes gamma locus cells Whitney et al. 209995_s_at T-cell leukemia/ TCL1A Whitney et al. 203104_at colony stimulating CSF1R lymphoma 1A factor 1 receptor, Whitney et al. 210164_at granzyme B GZMB formerly McDonough (granzyme 2, feline sarcoma viral cytotoxic T-lymphocyte- (v-fms) oncogene associated serine homolog esterase 1) Whitney et al. 203290_at major histocompatibility HLA-DQA1 Whitney et al. 210321_at similar to granzyme B CTLA1 complex, class II, (granzyme 2, cytotoxic DQ alpha 1 T-lymphocyte-associated Whitney et al. 203413_at NEL-like 2 (chicken) NELL2 serine esterase 1) Whitney et al. 203828_s_at natural killer cell NK4 (H. sapiens) transcript 4 Whitney et al. 212827_at immunoglobulin heavy IGHM Whitney et al. 203932_at major histocompatibility HLA-DMB constant mu complex, class II, Whitney et al. 212998_x_at major histocompatibility HLA-DQB1 DM beta complex, class II, Whitney et al. 204655_at chemokine (C-C motif) CCL5 DQ beta 1 ligand 5 Whitney et al. 212999_x_at major histocompatibility HLA-DQB Whitney et al. 204661_at CDW52 antigen CDW52 complex, class II, (CAMPATH-1 antigen) DQ beta 1 Whitney et al. 205049_s_at CD79A antigen CD79A Whitney et al. 213193_x_at T cell receptor beta locus TRB (immunoglobulin- Whitney et al. 213425_at Homo sapiens cDNA associated alpha) FLJ11441 fis, clone Whitney et al. 205291_at interleukin 2 receptor, IL2RB HEMBA1001323, beta mRNA sequence Whitney et al.
    [Show full text]